Burning Rock Biotech vs Guardant Health
BNR and GH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNR and GH compare
Guardant Health grew revenue faster over the last twelve months (42.7% versus 4.6% for Burning Rock Biotech).
Burning Rock Biotech keeps more of each dollar of sales as profit, with a net margin of −10.3% compared with −38.3% at Guardant Health.
Guardant Health scores higher on the StockData Score (9 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNR | GH |
|---|---|---|
| Size and price | ||
| Market cap | – | $24.0B |
| Share price | $10.90 | $178.80 |
| Change, 1 year | −13.0% | 147% |
| Change, 5 years | −92.6% | 62.3% |
| Beta (5Y) | 1.79 | 1.61 |
| Employees | 667 | 2,506 |
| StockData Score | ||
| Total score | 4 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 20.3× |
| FCF yield | – | −1.0% |
| Growth | ||
| Revenue growth (TTM) | 4.6% | 42.7% (better) |
| Revenue growth, 5Y average | 4.6% | 27.9% (better) |
| Profitability | ||
| Gross margin | 74.7% (better) | 65.0% |
| Operating margin | −10.2% (better) | −39.7% |
| Net margin | −10.3% (better) | −38.3% |
| FCF margin | −6.2% (better) | −20.3% |
| Return on equity | −9.9% | – |
| Return on invested capital | −72.5% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −97.6× |
| Current ratio | 2.99 | 4.03 (better) |
| Altman Z-score | – | 4.83 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.8% | 99.8% |
| Held by insiders | 19.0% | 1.9% |
| Insider net buying, 12 months | $11.6M (better) | −$174M |
| Short interest, % of float | – | 9.1% |
Go deeper
- BNR stock overview
- BNR income statement
- BNR valuation and score
- GH stock overview
- GH income statement
- GH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.